About FSHD Canada Foundation

FSHD clinical trials are coming to Canada – get registered here: Canadian Neuromuscular Disease Registry

Funded Research

Biomarkers

Investigators: Yi-Wen Chen (Children’s National Hospital, Washington, DC) Giorgio Tasca & Enzo Ricci (Università Cattolica del Sacro Cuore – Rome) Sabrina Sacconi (Centre Hospitalier Universitaire de Nice) Biomarkers are used…

Read More

Clinical Trial Research Network (CTRN)

Investigators: Jeffrey Statland (University of Kansas Medical Center) and Rabi Tawil (University of Rochester Medical Center) This project includes support for the CTRN to continue the Natural History Studies (MOVE…

Read More

Muscle targeted immunosuppression as an FSHD therapeutic

Investigator: Andreia Marcelino Nunes, PhD; University of Nevada, Reno School of Medicine FSHD is caused by aberrant increased expression of the DUX4 gene in skeletal myocytes, which initiates a pathogenic…

Read More

Generation of porcine large animal models for FSHD therapeutic development and preclinical testing

Investigators: Peter L. Jones Lab; University of Nevada, Reno School of Medicine The primary therapeutic target in all forms of FSHD is DUX4-fl mRNA and DUX4-FL protein, and animal models…

Read More

Motor Outcomes to Validate Evaluations in FSHD

Investigators: Jeffrey Statland, PI (University of Kansas Medical Center); and Rabi Tawil, Co-PI (University of Rochester Medical Center) The primary goal of this proposal is to hasten therapeutic development for…

Read More

Facio Therapies

Facio Therapies, established in 2014, is a Netherlands-based company with a single focus – to overcome FSHD by developing a causal therapy that restores the natural repression of muscle-toxic DUX4.…

Read More
https://twitter.com/#!/FSHDCanada/ http://www.facebook.com/pages/FSHD-Canada/331378503625267 /contact Suite 201, 1100 1st St. SE Calgary, Alberta T2G 1B1 403.470.0141 neil.camarta@fshd.ca